Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 May 14;5(5):CD009880.
doi: 10.1002/14651858.CD009880.pub3.

A comparison of different antibiotic regimens for the treatment of infective endocarditis

Arturo J Martí-Carvajal  1   2 , Mark Dayer  3 , Lucieni O Conterno  4 , Alejandro G Gonzalez Garay  5 , Cristina Elena Martí-Amarista  6
Affiliations
Meta-Analysis

A comparison of different antibiotic regimens for the treatment of infective endocarditis

Arturo J Martí-Carvajal et al. Cochrane Database Syst Rev. .

Abstract

Background: Infective endocarditis is a microbial infection of the endocardial surface of the heart. Antibiotics are the cornerstone of treatment, but due to the differences in presentation, populations affected, and the wide variety of micro-organisms that can be responsible, their use is not standardised. This is an update of a review previously published in 2016.

Objectives: To assess the existing evidence about the clinical benefits and harms of different antibiotics regimens used to treat people with infective endocarditis.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase Classic and Embase, LILACS, CINAHL, and the Conference Proceedings Citation Index - Science on 6 January 2020. We also searched three trials registers and handsearched the reference lists of included papers. We applied no language restrictions.

Selection criteria: We included randomised controlled trials (RCTs) assessing the effects of antibiotic regimens for treating definitive infective endocarditis diagnosed according to modified Duke's criteria. We considered all-cause mortality, cure rates, and adverse events as the primary outcomes. We excluded people with possible infective endocarditis and pregnant women.

Data collection and analysis: Two review authors independently performed study selection, 'Risk of bias' assessment, and data extraction in duplicate. We constructed 'Summary of findings' tables and used GRADE methodology to assess the quality of the evidence. We described the included studies narratively.

Main results: Six small RCTs involving 1143 allocated/632 analysed participants met the inclusion criteria of this first update. The included trials had a high risk of bias. Three trials were sponsored by drug companies. Due to heterogeneity in outcome definitions and different antibiotics used data could not be pooled. The included trials compared miscellaneous antibiotic schedules having uncertain effects for all of the prespecified outcomes in this review. Evidence was either low or very low quality due to high risk of bias and very low number of events and small sample size. The results for all-cause mortality were as follows: one trial compared quinolone (levofloxacin) plus standard treatment (antistaphylococcal penicillin (cloxacillin or dicloxacillin), aminoglycoside (tobramycin or netilmicin), and rifampicin) versus standard treatment alone and reported 8/31 (26%) with levofloxacin plus standard treatment versus 9/39 (23%) with standard treatment alone; risk ratio (RR) 1.12, 95% confidence interval (CI) 0.49 to 2.56. One trial compared fosfomycin plus imipenem 3/4 (75%) versus vancomycin 0/4 (0%) (RR 7.00, 95% CI 0.47 to 103.27), and one trial compared partial oral treatment 7/201 (3.5%) versus conventional intravenous treatment 13/199 (6.53%) (RR 0.53, 95% CI 0.22 to 1.31). The results for rates of cure with or without surgery were as follows: one trial compared daptomycin versus low-dose gentamicin plus an antistaphylococcal penicillin (nafcillin, oxacillin, or flucloxacillin) or vancomycin and reported 9/28 (32.1%) with daptomycin versus 9/25 (36%) with low-dose gentamicin plus antistaphylococcal penicillin or vancomycin; RR 0.89, 95% CI 0.42 to 1.89. One trial compared glycopeptide (vancomycin or teicoplanin) plus gentamicin with cloxacillin plus gentamicin (13/23 (56%) versus 11/11 (100%); RR 0.59, 95% CI 0.40 to 0.85). One trial compared ceftriaxone plus gentamicin versus ceftriaxone alone (15/34 (44%) versus 21/33 (64%); RR 0.69, 95% CI 0.44 to 1.10), and one trial compared fosfomycin plus imipenem versus vancomycin (1/4 (25%) versus 2/4 (50%); RR 0.50, 95% CI 0.07 to 3.55). The included trials reported adverse events, the need for cardiac surgical interventions, and rates of uncontrolled infection, congestive heart failure, relapse of endocarditis, and septic emboli, and found no conclusive differences between groups (very low-quality evidence). No trials assessed quality of life.

Authors' conclusions: This first update confirms the findings of the original version of the review. Limited and low to very low-quality evidence suggests that the comparative effects of different antibiotic regimens in terms of cure rates or other relevant clinical outcomes are uncertain. The conclusions of this updated Cochrane Review were based on few RCTs with a high risk of bias. Accordingly, current evidence does not support or reject any regimen of antibiotic therapy for the treatment of infective endocarditis.

PubMed Disclaimer

Conflict of interest statement

Arturo Martí‐Carvajal: in 2004 Arturo Martí‐Carvajal was employed by Eli Lilly to run a four‐hour workshop on 'How to critically appraise clinical trials on osteoporosis and how to teach this'. This activity was not related to his work with Cochrane or any Cochrane Review. In 2007, Arturo Martí‐Carvajal was employed by Merck to run a four‐hour workshop on 'How to critically appraise clinical trials and how to teach this'. This activity was not related to his work with Cochrane or any Cochrane Review.

Mark Dayer is currently undertaking clinical trials, sponsored by Novartis, in the field of heart failure. He has received no direct funding from Novartis since 2008, when the company sponsored his attendance at the European Society of Cardiology. Novartis is the manufacturer of daptomycin. In 2015, Dr Dayer received educational sponsorship from Bayer. He received advisory board fees from Res‐Med (2014 to 2015), Daiichi‐Sankyo (2015), and St Jude (2015 to 2016). Between 2007 and 2015, Dr Dayer also received educational sponsorship/speaker fees from Boehringer‐Ingelheim, Pfizer, Boston Scientific, Medtronic, Biotronik, and Sorin.

Lucieni Oliveira Conterno, Alejandro González Garay, and Cristina Martí‐Amarista have no known conflicts of interest.

None of the authors of this review were authors on the studies considered by this review.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

FINLEVO Trial 2006 {published data only}
    1. Ruotsalainen E, Järvinen A, Koivula I, Kauma H, Rintala E, Lumio J, Finlevo Study Group. Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. Journal of Internal Medicine 2006;259(2):179-90. [PMID: ] - PubMed
Fortún 2001 {published data only}
    1. Fortún J, Navas E, Martínez-Beltrán J, Pérez-Molina J, Martín-Dávila P, Guerrero A, et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clinical Infectious Diseases 2001;33(1):120-5. [PMID: ] - PubMed
Fowler 2006 {published data only}
    1. Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clinical Infectious Diseases 2009;48(6):713-21. [PMID: ] - PubMed
    1. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. New England Journal of Medicine 2006;355(7):653-65. [PMID: ] - PubMed
    1. Kanafani Z, Boucher H, Fowler V, Cabell C, Hoen B, Miro JM, et al. Daptomycin compared to standard therapy for the treatment of native valve endocarditis. Enfermedades Infecciosas y Microbiología Clínica 2010;28(8):498-503. [PMID: ] - PubMed
    1. Rehm SJ, Boucher H, Levine D, Campion M, Eisenstein BI, Vigliani GA, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. Journal of Antimicrobial Chemotherapy 2008;62(6):1413-21. [PMID: ] - PMC - PubMed
Pericas 2018 {published data only}
    1. Pericàs JM, Moreno A, Almela M, García de la Mària C, Marco F, Muñoz P, FOSIMI Investigators. Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial. Clinical Microbiology and Infections 2018;24(6):673-6. [PMID: ] - PubMed
    1. Rio A, Gasch O, Moreno A, Pena C, Cuquet J, Soy D, et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clinical Infectious Diseases 2014;59(8):1105-12. [PMID: ] - PubMed
POET 2019 {published data only}
    1. Iversen K, Host N, Bruun NE, Elming H, Pump B, Christensen JJ, et al. Partial oral treatment of endocarditis. American Heart Journal 2013;165(2):116-22. [PMID: ] - PubMed
    1. Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. New England Journal of Medicine 2019;380(5):415-24. [PMID: ] - PubMed
Sexton 1998 {published data only}
    1. Sexton D, Tenenbaum M, Wilson W, Steckelberg J, Tice A, Gilbert D, et al. Ceftriaxone once daily for four weeks vs. ceftriaxone plus gentamicin for two weeks for the treatment of penicillin susceptible Streptococcal endocarditis. Clinical Infectious Diseases 1996;4:23889. - PubMed
    1. Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, Tice AD, Gilbert D, et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clinical Infectious Diseases 1998;27(6):1470-4. [PMID: 9868662] - PubMed

References to studies excluded from this review

Abrams 1979 {published data only}
    1. Abrams B, Sklaver A, Hoffman T, Greenman R. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Annals of Internal Medicine 1979;90(5):789-91. [PMID: ] - PubMed
Fortún 1995 {published data only}
    1. Fortún J, Pérez-Molina JA, Añón MT, Martínez-Beltrán J, Loza E, Guerrero A. Right-sided endocarditis caused by Staphylococcus aureus in drug abusers. Antimicrobial Agents and Chemotherapy 1995;39(2):525-8. [PMID: ] - PMC - PubMed
Gilbert 1991 {published data only}
    1. Gilbert DN, Wood CA, Kimbrough RC. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon. Antimicrobial Agents and Chemotherapy 1991;35(1):79-87. [PMID: ] - PMC - PubMed
Greenman 1984 {published data only}
    1. Greenman RL, Arcey SM, Gutterman DA, Zweig RM. Twice-daily intramuscular ceforanide therapy of Staphylococcus aureus endocarditis in parenteral drug abusers. Antimicrobial Agents and Chemotherapy 1984;25(1):16-9. [PMID: ] - PMC - PubMed
Heldman 1996 {published data only}
    1. Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. American Journal of Medicine 1996;101(1):68-76. [PMID: ] - PubMed
Korzeniowski 1982 {published data only}
    1. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Annals of Internal Medicine 1982;97(4):496-503. [PMID: ] - PubMed
Levine 1991 {published data only}
    1. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Annals of Internal Medicine 1991;115(9):674-80. [PMID: ] - PubMed
Markowitz 1992 {published data only}
    1. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Annals of Internal Medicine 1992;117(5):390-8. [PMID: 1503330] - PubMed
Ribera 1996 {published data only}
    1. Ribera E, Gomez-Jimenez J, Cortes E, Valle O, Planes A, Gonzalez-Alujas T, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Annals of Internal Medicine 1996;125(12):969-74. [PMID: ] - PubMed
Stamboulian 1991 {published data only}
    1. Stamboulian D, Bonvehi P, Arevalo C, Bologna R, Cassetti I, Scilingo V, et al. Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Reviews of Infectious Diseases 1991;13(Suppl 2):160-3. [PMID: ] - PubMed

References to ongoing studies

CTRI/2008/091/000060 {published data only}
    1. CTRI/CTRI/2008/091/000060. A clinical trial to study the safety and efficacy of combination drug, vancomycin and ceftriaxone compared to vancomycin in mild to severe bacterial infections. who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2008/091/000060 (date registered 7 May 2008).
EUCTR 2016‐003059‐31 {published data only}
    1. EUCTR 2016-003059-31. Study to assess the efficacy, safety and pharmacokinetics of CF-301 compared with placebo in addition to standard-of-care antibiotic therapy in blood infections caused by S. aureus, including heart valve infections. who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2016-003059-31 (start date 2 November 2017).
EUCTR 2017‐001699‐43 {published data only}
    1. EUCTR2017-001699-43. A study to assess the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including infective endocarditis. who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017-001699-43 (start date 13 December 2018).
EudraCT 2008‐008683‐28 {published data only}
    1. EUCTR 2008-008683-28. Evaluación de la eficacia y la seguridad de la combinación de fosfomicina (F) e imipenem (I) para el tratamiento de la endocarditis infecciosa (EI) sobre válvula nativa o protésica por S. Aureus resistente a meticilina (SARM). who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-008683-28 (start date 23 September 2009).
JPRN‐UMIN 000032006 {published data only}
    1. JPRN-UMIN 000032006. An open-label randomized controlled trial of ampicillin/cloxacillin and ceftriaxone for empirical treatment of infective endocarditis. who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000032006 (first received 31 March 2018).
NCT00638157 {published data only}
    1. NCT00638157. Phase 4 Efficacy and safety study of cubicin® with and without combination therapy in S. aureus infective endocarditis (SAIE). clinicaltrials.gov/ct2/show/NCT00638157 (first received 18 March 2008).
NCT00695903 {published data only}
    1. NCT00695903. Phase 2 study of safety, efficacy, and pharmacokinetics of higher doses of daptomycin and vancomycin in MRSA bacteremia (HDSAB). clinicaltrials.gov/ct2/show/NCT00695903 (first received 12 June 2008).
NCT02208063 {published data only}
    1. NCT02208063. A phase 3 telavancin Staphylococcus aureus (S. aureus) bacteremia trial. clinicaltrials.gov/ct2/show/NCT02208063 (first received 4 August 2014).
NCT02701595 {published data only}
    1. NCT02701595. Oral switch during treatment of left-sided endocarditis due to multi-susceptible streptococcus. clinicaltrials.gov/ct2/show/NCT02701595 (first received 8 March 2016).
NCT02701608 {published data only}
    1. NCT02701608. Oral switch during treatment of left-sided endocarditis due to multi-susceptible staphylococcus. clinicaltrials.gov/ct2/show/NCT02701608 (first received 8 March 2016).
NCT03138733 {published data only}
    1. NCT03138733. Ceftobiprole in the treatment of patients with Staphylococcus aureus bacteremia. clinicaltrials.gov/show/nct03138733 (first received 3 May 2017).
NCT03148756 {published data only}
    1. NCT03148756. Efficacy and safety of dalbavancin compared to standard of care antibiotic therapy for the completion of treatment of patients with complicated bacteremia or infective endocarditis. clinicaltrials.gov/show/nct03148756 (first received 11 May 2017).
NCT04222257 {published data only}
    1. NCT04222257. Short-course antibiotic treatment in gram-positive cocci infective endocarditis (SATIE). clinicaltrials.gov/ct2/show/NCT04222257 (first received 9 January 2020).
RBR‐3p8g7n 2016 {published data only}
    1. RBR-3p8g7n. Clinical trial of telavancin versus standard intravenous therapy in the treatment of subjects with Staphylococcus aureus bacteremia including infective endocarditis. apps.who.int/trialsearch/Trial2.aspx?TrialID=RBR-3p8g7n (first received 3 August 2016).

Additional references

Amat‐Santos 2015
    1. Amat-Santos IJ, Ribeiro HB, Urena M, Allende R, Houde C, Bedard E, et al. Prosthetic valve endocarditis after transcatheter valve replacement: a systematic review. JACC. Cardiovascular Interventions 2015;8(2):334-46. [PMID: ] - PubMed
Ambrosioni 2017
    1. Ambrosioni J, Hernandez-Meneses M, Tellez A, Pericas J, Falces C, Tolosana JM, et al. The changing epidemiology of infective endocarditis in the Twenty-First Century. Current Infectious Disease Reports 2017;19(5):21. [PMID: ] - PubMed
Anderson 2008
    1. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 2008;68(4):535-65. [PMID: 18318569] - PubMed
Asai 2019
    1. Asai N, Shiota A, Ohashi W, Watanabe H, Shibata Y, Kato H, et al. The SOFA score could predict the severity and prognosis of infective endocarditis. Journal of Infection and Chemotherapy 2019;25(12):965-71. [PMID: ] - PubMed
Avelana 2018
    1. Avelana PM, Aurelio M, Swieszkowski S, Nacinovich F, Kazelian L, Spenato M, et al. Infective endocarditis in Argentina. Results of the EIRA 3 study [Endocarditis infecciosa en la República Argentina. Resultados del estudio EIRA 3]. Revista Argentina de Cardiología 2018;86(1):21-9. [biblio-990513]
Ba 2017
    1. Ba DM, Mboup MC, Zeba N, Dia K, Fall AN, Fall F, et al. Infective endocarditis in Principal Hospital of Dakar: a retrospective study of 42 cases over 10 years. Pan African Medical Journal 2017;26:40. [PMID: ] - PMC - PubMed
Baddour 2015
    1. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015;132(15):1435-86. [PMID: ] - PubMed
Bai 2017
    1. Bai AD, Agarwal A, Steinberg M, Showler A, Burry L, Tomlinson GA, et al. Clinical predictors and clinical prediction rules to estimate initial patient risk for infective endocarditis in Staphylococcus aureus bacteraemia: a systematic review and meta-analysis. Clinical Microbiology and Infection 2017;23(12):900-6. [PMID: ] - PubMed
Balshem 2011
    1. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [PMID: ] - PubMed
Basch 2012
    1. Basch E, Aronson N, Berg A, Flum D, Gabriel S, Goodman SN, et al. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA 2012;307(15):1636-40. [PMID: ] - PubMed
Bayer 1994
    1. Bayer AS, Ward JI, Ginzton LE, Shapiro SM. Evaluation of new clinical criteria for the diagnosis of infective endocarditis. American Journal of Medicine 1994;96(3):211-9. [PMID: ] - PubMed
Beganovic 2018
    1. Beganovic M, Luther MK, Rice LB, Arias CA, Rybak MJ, LaPlante KL. A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis. Clinical Infectious Diseases 2018;67(2):303-9. [PMID: ] - PMC - PubMed
Beteille 2018
    1. Beteille E, Guarana M, Nucci M. Infective endocarditis in neutropenic patients with viridans streptococci bacteraemia. Clinical Microbiology and Infection 2018;24(8):916-7. [PMID: ] - PubMed
Burgos 2019
    1. Burgos LM, Cracco MA, Fernandez Oses P, Iribarren AC, Ronderos R, Nacinovich F. Infective endocarditis in Argentina: what have we learned in the last 25 years ? [Endocardtis infecciosa en ARGENTINA: ¿Qué aprendimos en los últimos 25 años?]. Medicina 2019;79(4):257-64. [PMID: ] - PubMed
Cahill 2016
    1. Cahill TJ, Prendergast BD. Infective endocarditis. Lancet 2016;387(10021):882-93. [PMID: ] - PubMed
Cantier 2019
    1. Cantier M, Sabben C, Adle-Biassette H, Louedec L, Delbosc S, Desilles JP, et al. Neurologic complications of infective endocarditis: a joint model for a septic thromboembolism and inflammatory small vessel disease. Critical Care Medicine 2019;47(8):e685-92. [PMID: ] - PubMed
Cao 2018
    1. Cao GF, Liu W, Bi Q. Stroke in patients with infective endocarditis: a 15-year single-center cohort study. European Neurology 2018;80(3-4):171-8. [PMID: ] - PubMed
Cecchi 2015
    1. Cecchi E, Chirillo F, Castiglione A, Faggiano P, Cecconi M, Moreo A, et al. Clinical epidemiology in Italian registry of infective endocarditis (RIEI): focus on age, intravascular devices and enterococci. International Journal of Cardiology 2015;190:151-6. [PMID: ] - PubMed
Chambers 2001a
    1. Chambers HF. The aminoglycosides. In: Hardman JG, Limbird LE, editors(s). Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 10th edition. New York: McGraw Hill, 2001:1219-38. [ISBN: 0-07-135469-7]
Chambers 2001b
    1. Chambers HF. Protein synthesis inhibitors and miscellaneous antibacterial agents. In: Hardman JG, Limbird LE, editors(s). Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 10th edition. New York: McGraw Hill, 2001:1239-71. [ISBN: 0-07-135469-7]
Champey 2016
    1. Champey J, Pavese P, Bouvaist H, Kastler A, Krainik A, Francois P. Value of brain MRI in infective endocarditis: a narrative literature review. European Journal of Clinical Microbiology and Infectious Diseases 2016;35(2):159-68. [PMID: ] - PMC - PubMed
Chan 2013
    1. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. [PMID: ] - PMC - PubMed
Chen 2009
    1. Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Infectious Disease Clinics of North America 2009;23(4):1053-75. [PMID: ] - PubMed
Chopra 2007
    1. Chopra P, Gulwani H. Pathology and pathogenesis of rheumatic heart disease. Indian Journal of Pathology & Microbiology 2007;50(4):685-97. [PMID: ] - PubMed
Colomer‐Winter 2018
    1. Colomer-Winter C, Gaca AO, Chuang-Smith ON, Lemos JA, Frank KL. Basal levels of (p)ppGpp differentially affect the pathogenesis of infective endocarditis in Enterococcus faecalis. Microbiology 2018;164(10):1254-65. [PMID: ] - PMC - PubMed
Cosgrove 2009
    1. Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clinical Infectious Diseases 2009;48(6):713-21. [PMID: ] - PubMed
Cresti 2017
    1. Cresti A, Chiavarelli M, Scalese M, Nencioni C, Valentini S, Guerrini F, et al. Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study. Cardiovascular Diagnosis and Therapy 2017;7(1):27-35. [PMID: ] - PMC - PubMed
Cunha 2015
    1. Cunha BA, Brahmbhatt K, Raza M. Haemophilus parainfluenzae aortic prosthetic valve endocarditis (PVE) successfully treated with oral levofloxacin. Heart and Lung 2015;44(4):317-20. [PMID: 25998992] - PubMed
Daga 2011
    1. Daga S, Shepherd J, Callaghan G, Hung R, Dawson D, Padfield G, et al. Platelet receptor polymorphisms do not influence Staphylococcus aureus-platelet interactions or infective endocarditis. Microbes and Infection 2011;13(3):216-25. [PMID: ] - PMC - PubMed
Damasco 2019
    1. Damasco PV, Correal JCD, Cruz-Campos ACD, Wajsbrot BR, Cunha RGD, Fonseca AGD, et al. Epidemiological and clinical profile of infective endocarditis at a Brazilian tertiary care center: an eight-year prospective study. Revista da Sociedade Brasileira de Medicina Tropical 2019;52:e2018375. [PMID: ] - PubMed
de Jong 2019
    1. Jong NWM, Kessel KPM, Strijp JAG. Immune evasion by Staphylococcus aureus. Microbiology Spectrum 2019;7(2):GPP3-0061-2019. [PMID: ] - PMC - PubMed
Delahaye 2019
    1. Delahaye F, De Gevigney G. Infective endocarditis and specific situations: right heart, valve prosthesis, cardiac implantable electronic device [Endocardites infectieuses: formes particulieres (coeur droit, prothese valvulaire, dispositif electronique intracardiaque)]. Presse Medicale 2019;48(5):549-55. [PMID: ] - PubMed
Delorme 2016
    1. Delorme P, Micheaux PL, Liquet B, Riou J. Type-II generalized family-wise error rate formulas with application to sample size determination. Statistics in Medicine 2016;35(16):2687-714. [PMID: ] - PubMed
Dhotre 2018
    1. Dhotre S, Jahagirdar V, Suryawanshi N, Davane M, Patil R, Nagoba B. Assessment of periodontitis and its role in viridans streptococcal bacteremia and infective endocarditis. Indian Heart Journal 2018;70(2):225-32. [PMID: ] - PMC - PubMed
Drees 2006
    1. Drees M, Boucher H. New agents for Staphylococcus aureus endocarditis. Current Opinion in Infectious Diseases 2006;19(6):544-50. [PMID: ] - PubMed
Dryden 2011
    1. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. Journal of Antimicrobial Chemotherapy 2011;66(Suppl 4):iv7-15. [PMID: ] - PubMed
Durack 1994
    1. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. American Journal of Medicine 1994;96(3):200-9. [PMID: ] - PubMed
Egbe 2019
    1. Egbe AC, Vallabhajosyula S, Akintoye E, Connolly HM. Trends and outcomes of infective endocarditis in adults with tetralogy of Fallot: a review of the national inpatient sample database. Canadian Journal of Cardiology 2019;35(6):721-6. [PMID: ] - PubMed
El Rafei 2016
    1. El Rafei A, DeSimone DC, DeSimone CV, Lahr BD, Steckelberg JM, Sohail MR, et al. Beta-haemolytic streptococcal endocarditis: clinical presentation, management and outcomes. Infectious Diseases (London, England) 2016;48(5):373-8. [PMID: ] - PubMed
Elbatarny 2019
    1. Elbatarny M, Bahji A, Bisleri G, Hamilton A. Management of endocarditis among persons who inject drugs: a narrative review of surgical and psychiatric approaches and controversies. General Hospital Psychiatry 2019;57:44-9. [PMID: ] - PubMed
Elmistekawy 2016
    1. Elmistekawy E, Chan V, Mesana T. Surgical management: indications, timing and surgical techniques. In: Chan K-L, Embil JM, editors(s). Endocarditis: Diagnosis and Management. London: Springer-Verlag, 2016:153-79. [DOI: 10.1007/978-3-319-27784-4_8] - DOI
Erdem 2019
    1. Erdem H, Puca E, Ruch Y, Santos L, Ghanem-Zoubi N, Argemi X, et al. Portraying infective endocarditis: results of multinational ID-IRI study. European Journal of Clinical Microbiology and Infectious Diseases 2019;38(9):1753-63. [PMID: ] - PubMed
Falagas 2006
    1. Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. Journal of Antimicrobial Chemotherapy 2006;57(4):639-47. [PMID: ] - PubMed
Falagas 2007
    1. Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. Journal of Antimicrobial Chemotherapy 2007;60(1):7-19. [PMID: ] - PubMed
Flemming 2010
    1. Flemming HC, Wingender J. The biofilm matrix. Nature Reviews. Microbiology 2010;8(9):623-33. [PMID: ] - PubMed
Flemming 2016
    1. Flemming HC, Wingender J, Szewzyk U, Steinberg P, Rice SA, Kjelleberg S. Biofilms: an emergent form of bacterial life. Nature Reviews. Microbiology 2016;14(9):563-75. [PMID: ] - PubMed
Frank 2009
    1. Frank U, Tacconelli E. Treatment of the most frequent types of bacterial endocarditis. In: Frank U, Tacconelli E, editors(s). The Daschner Guide to In-Hospital Antibiotic Therapy. Heidelberg: Springer Medizin Verlag, 2009:211-4. [ISBN: 978-3-540-48347-2]
Gabriel 2012
    1. Gabriel SE, Normand SL. Getting the methods right - the Foundation of Patient-Centered Outcomes Research. New England Journal of Medicine 2012;367(9):787-90. [PMID: ] - PubMed
Giacobbe 2019
    1. Giacobbe DR, Corcione S, Salsano A, Del Puente F, Mornese Pinna S, De Rosa FG, et al. Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery. Expert Opinion on Pharmacotherapy 2019;20(6):751-72. [PMID: ] - PubMed
Gould 2011
    1. Gould FK. Linezolid: safety and efficacy in special populations. Journal of Antimicrobial Chemotherapy 2011;66(Suppl 4):iv3-6. [PMID: ] - PubMed
GRADEpro 2008 [Computer program]
    1. The GRADE Working Group GRADEpro. Brozek J, Oxman A, Schünemann H, Version 3.2 for Windows. The GRADE Working Group, 2008.
Granowitz 2008
    1. Granowitz EV, Brown RB. Antibiotic adverse reactions and drug interactions. Critical Care Clinics 2008;24(2):421-42. [PMID: ] - PubMed
Grisoli 2014
    1. Grisoli D, Million M, Edouard S, Thuny F, Lepidi H, Collart F, et al. Latent Q fever endocarditis in patients undergoing routine valve surgery. Journal of Heart Valve Disease 2014;23(6):735-43. [PMID: ] - PubMed
Guerra 2017
    1. Guerra FE, Borgogna TR, Patel DM, Sward EW, Voyich JM. Epic immune battles of history: neutrophils vs. Staphylococcus aureus. Frontiers in Cellular and Infection Microbiology 2017;7:286. [PMID: ] - PMC - PubMed
Gupta 2011
    1. Gupta A, Biyani M, Khaira A. Vancomycin nephrotoxicity: myths and facts. Netherlands Journal of Medicine 2011;69(9):379-83. [PMID: ] - PubMed
Guyatt 2008
    1. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ 2008;336(7651):995-8. [PMID: ] - PMC - PubMed
Guyatt 2011a
    1. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PMID: ] - PubMed
Guyatt 2011b
    1. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PMID: ] - PubMed
Guyatt 2011c
    1. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PMID: ] - PubMed
Guyatt 2011d
    1. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PMID: ] - PubMed
Guyatt 2011e
    1. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6. [PMID: ] - PubMed
Guyatt 2011f
    1. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [PMID: ] - PubMed
Guyatt 2011g
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PMID: ] - PubMed
Guyatt 2011h
    1. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400. [PMID: ] - PubMed
Habib 2015
    1. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, ESC Scientific Document Group. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). European Heart Journal 2015;36(44):3075-128. [PMID: 26320109] - PubMed
Habib 2019
    1. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. European Heart Journal 2019;40(39):3222-32. [PMID: ] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [PMID: ] - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hitzenbichler 2019
    1. Hitzenbichler F, Olic J, Hanses F, Salzberger B, Fischer M, Baessler A. Current treatment of endocarditis: innovations and controversies [Aktuelle therapie der endokarditis: neuerungen und kontroversen]. Der Internist 2019;60(10):1111-17. [PMID: ] - PubMed
Hoen 2006
    1. Hoen B. Epidemiology and antibiotic treatment of infective endocarditis: an update. Heart 2006;92(11):1694-700. [PMID: ] - PMC - PubMed
Holland 2016
    1. Holland TL, Baddour LM, Bayer AS, Hoen B, Miro JM, Fowler VG Jr. Infective endocarditis. Nature Reviews. Disease Primers 2016;2:16059. [PMID: ] - PMC - PubMed
Hollis 1999
    1. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-4. [PMID: ] - PMC - PubMed
Humphries 2013
    1. Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clinical Microbiology Reviews 2013;26(4):759-80. [PMID: ] - PMC - PubMed
Ioannidis 2004
    1. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781-8. [PMID: ] - PubMed
Ioannidis 2010
    1. Ioannidis JP. Meta-research: the art of getting it wrong. Research Synthesis Methods 2010;10(3-4):169-84. - PubMed
Iung 2019a
    1. Iung B, Duval X. Infective endocarditis: innovations in the management of an old disease. Nature Reviews. Cardiology 2019;16(10):623-35. [PMID: 31175343 ] - PubMed
Iung 2019b
    1. Iung B. Infective endocarditis. Epidemiology, pathophysiology and histopathology [Endocardite infectieuse. Epidemiologie, physiopathologie et anatomopathologie]. Presse Medicale 2019;48(5):513-21. [PMID: ] - PubMed
Jakuska 2019
    1. Jakuska P, Ereminiene E, Muliuolyte E, Kosys V, Pavlavicius L, Zukovas G, et al. Predictors of early mortality after surgical treatment of infective endocarditis: a single-center experience. Perfusion 2019;Sep 4:Online ahead of print.. [DOI: 10.1177/0267659119872345] [PMID: ] - DOI - PubMed
Jung 2015
    1. Jung CJ, Yeh CY, Hsu RB, Lee CM, Shun CT, Chia JS. Endocarditis pathogen promotes vegetation formation by inducing intravascular neutrophil extracellular traps through activated platelets. Circulation 2015;131(6):571-81. [PMID: ] - PubMed
Karchmer 2009
    1. Karchmer AW. Infective endocarditis. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al, editors(s). Harrison's Principles of Internal Medicine. 17th edition. New York: McGraw-Hill, 2009:440-7. [ISBN: 978-0-07-147743-7]
Keynan 2013
    1. Keynan Y, Rubinstein E. Pathophysiology of infective endocarditis. Current Infectious Disease Reports 2013;15(4):342-6. [PMID: ] - PubMed
Khan 2017
    1. Khan ZA, Hollenberg SM. Valvular heart disease in adults: infective endocarditis. FP Essentials 2017;457:30-8. [PMID: ] - PubMed
Kobayashi 2019
    1. Kobayashi T, Ando T, Streit J, Sekar P. Current evidence on oral antibiotics for infective endocarditis: a narrative review. Cardiology and Therapy 2019;8(2):167-77. [PMID: 31535282] - PMC - PubMed
Krčméry 2019
    1. Krčméry V, Hricak V, Fischer V, Mrazova M, Brnova J, Hulman M, et al. Etiology, risk factors and outcome of 1003 cases of infective endocarditis from a 33-year National Survey in the Slovak Republic: an increasing proportion of elderly patients. Neuro Endocrinology Letters 2019;39(8):544-9. [PMID: ] - PubMed
Kumar 2019
    1. Kumar M, Anstadt EJ, Lopetegui Lia N, Siddiqi MH. Streptococcus viridans endocarditis affecting all four valves. Cureus 2019;11(5):e4635. [PMID: ] - PMC - PubMed
Lagace‐Wiens 2012
    1. Lagace-Wiens P, Rubinstein E. Adverse reactions to beta-lactam antimicrobials. Expert Opinion on Drug Safety 2012;11(3):381-99. [PMID: ] - PubMed
Leach 2011
    1. Leach KL, Brickner SJ, Noe MC, Miller PF. Linezolid, the first oxazolidinone antibacterial agent. Annals of the New York Academy of Sciences 2011;1222:49-54. [PMID: ] - PubMed
Leahey 2019
    1. Leahey PA, LaSalvia MT, Rosenthal ES, Karchmer AW, Rowley CF. High morbidity and mortality among patients with sentinel admission for injection drug use-related infective endocarditis. Open Forum Infectious Diseases 2019;6(4):ofz089. [PMID: ] - PMC - PubMed
Leekha 2011
    1. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clinic Proceedings 2011;86:156-67. [PMID: 21282489] - PMC - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Leyva 2008
    1. Leyva S, Leyva E. Fluoroquinolonas. Mecanismos de acción y resistencia, estructura, síntesis y reacciones fisicoquímicas importantes para propiedades medicinales. Boletín de la Sociedad Química de México 2008;2(1):1-13.
Li 2000
    1. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clinical Infectious Diseases 2000;30(4):633-8. [PMID: ] - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009;62(10):e1-34. [PMID: ] - PubMed
Lin 2019
    1. Lin CJ, Chua S, Chung SY, Hang CL, Tsai TH. Diabetes mellitus: an independent risk factor of in-hospital mortality in patients with infective endocarditis in a new era of clinical practice. International Journal of Environmental Research and Public Health 2019;16(12):2248. [PMID: ] - PMC - PubMed
Liu 2010
    1. Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Safety 2010;33(5):353-69. [PMID: ] - PubMed
Lluri 2018
    1. Lluri G, Levi DS, Miller E, Hageman A, Sinha S, Sadeghi S, et al. Incidence and outcome of infective endocarditis following percutaneous versus surgical pulmonary valve replacement. Catheterization and Cardiovascular Interventions 2018;91(2):277-84. [PMID: ] - PubMed
Long 2018
    1. Long B, Koyfman A. Infectious endocarditis: an update for emergency clinicians. American Journal of Emergency Medicine 2018;36(9):1686-92. [PMID: ] - PubMed
Mascha 2018
    1. Mascha EJ, Vetter TR. Significance, errors, power, and sample size: the blocking and tackling of statistics. Anesthesia and Analgesia 2018;126(2):691-8. [PMID: ] - PubMed
McKinney 2012
    1. McKinney M. 'Time is of the essence'. PCORI moves to implement comparative effectiveness research, funding. Modern Healthcare 2012;42(5):12-3. [PMID: ] - PubMed
Melehani 2016
    1. Melehani JH, Duncan JA. Inflammasome activation can mediate tissue-specific pathogenesis or protection in Staphylococcus aureus infection. Current Topics in Microbiology and Immunology 2016;397:257-82. [PMID: ] - PMC - PubMed
Meshaal 2018
    1. Meshaal MS, Labib D, Said K, Hosny M, Hassan M, Abd Al Aziz S, et al. Aspergillus endocarditis: diagnostic criteria and predictors of outcome, a retrospective cohort study. PLOS ONE 2018;13(8):e0201459. [PMID: ] - PMC - PubMed
Mgbojikwe 2019
    1. Mgbojikwe N, Jones SR, Leucker TM, Brotman DJ. Infective endocarditis: beyond the usual tests. Cleveland Clinic Journal of Medicine 2019;86(8):559-67. [PMID: ] - PubMed
Moher 2010
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. [PMID: 20332511] - PMC - PubMed
Moriyama 2019
    1. Moriyama N, Laakso T, Biancari F, Raivio P, Jalava MP, Jaakkola J, et al. Prosthetic valve endocarditis after transcatheter or surgical aortic valve replacement with a bioprosthesis: results from the FinnValve Registry. EuroIntervention 2019;15(6):e500-7. [PMID: ] - PubMed
Moser 2017
    1. Moser C, Elming H, Helweg-Larsen J, Christensen JJ, Jensen KT, Smerup MH, et al. Infectious endocarditis. Danish guidelines [Infektiøs endocarditis]. www.nbv.cardio.dk/endocarditis (accessed 28 February 2019).
Murphy 2019
    1. Murphy DJ, Din M, Hage FG, Reyes E. Guidelines in review: Comparison of ESC and AHA guidance for the diagnosis and management of infective endocarditis in adults. Journal of Nuclear Cardiology 2019;26(1):303-8. [PMID: ] - PMC - PubMed
Muñoz 2007
    1. Muñoz P, Rodriguez-Creixems M, Moreno M, Marin M, Ramallo V, Bouza E. Linezolid therapy for infective endocarditis. Clinical Microbiology and Infection 2007;13(2):211-5. [PMID: ] - PubMed
Muñoz‐Moreno 2019
    1. Muñoz-Moreno MF, Ryan P, Alvaro-Meca A, Valencia J, Tamayo E, Resino S. National temporal trend analysis of infective endocarditis among patients infected with HIV in Spain (1997-2014): a retrospective study. Journal of Clinical Medicine 2019;8(8):E1167. [PMID: ] - PMC - PubMed
Naber 2001
    1. Naber CK, Bartel T, Eggebrecht H, Erbel R. Diagnosis of endocarditis today: Duke criteria or clinical judgment? [Endokarditisdiagnostik Heute: Duke-Kriterien oder klinische Einschatzung?]. Herz 2001;26(6):379-90. [PMID: ] - PubMed
Nagy 2018
    1. Nagy M, Alkady H, Abo Senna W, Abdelhay S. Predictors of surgical outcome in isolated prosthetic mitral valve endocarditis. Asian Cardiovascular and Thoracic Annals 2018;26(7):517-23. [PMID: ] - PubMed
Nailor 2009
    1. Nailor MD, Sobel JD. Antibiotics for Gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infectious Diseases Clinics of North America 2009;23(4):965-82. [PMID: 19909893 ] - PubMed
Nascimento 2019
    1. Nascimento CA. Embolic complications in infective endocarditis: how can we predict using a Risk Evaluator Score (SORTIE or ABCDE) [Complicações embólicas na endocardite infecciosa: como poderemos prever usando Escore Avaliador do Risco (ABCDE ou SORTIE)]. ABC Imagem Cardiovascular 2019;32(4):251-3. [PMID: ]
Nasser 2019
    1. Nasser A, Moradi M, Jazireian P, Safari H, Alizadeh-Sani M, Pourmand MR, et al. Staphylococcus aureus versus neutrophil: scrutiny of ancient combat. Microbial Pathogenesis 2019;131:259-69. [PMID: ] - PubMed
Nebeker 2004
    1. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine 2004;140(10):795-801. [PMID: ] - PubMed
Ogura 2019
    1. Ogura N, Tomari K, Takayama T, Tonegawa N, Okawa T, Matsuoka T, et al. Group A streptococcus endocarditis in children: 2 cases and a review of the literature. BMC Infectious Diseases 2019;19(1):102. [PMID: ] - PMC - PubMed
Olaison 1996
    1. Olaison L, Hogevik H. Comparison of the von Reyn and Duke criteria for the diagnosis of infective endocarditis: a critical analysis of 161 episodes. Scandinavian Journal of Infectious Diseases 1996;28(4):399-406. [PMID: ] - PubMed
Pabilona 2015
    1. Pabilona C, Gitler B, Lederman JA, Miller D, Keltz TN. Prosthetic valve endocarditis with valvular obstruction after transcatheter aortic valve replacement. Texas Heart Institute Journal 2015;42(2):172-4. [PMID: ] - PMC - PubMed
Paterson 2013
    1. Paterson DL. Determining research priorities for clinician-initiated trials in infectious diseases. Medical Journal of Australia 2013;198(5):270-2. [PMID: ] - PubMed
Petri 2001a
    1. Petri WA Jr. Penicillins, cephalosporins, and other β-lactam antibiotics. In: Hardman JG, Limbird LE, editors(s). Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 10th edition. New York: McGraw Hill, 2001:1189-218. [ISBN: 0-07-135469-7]
Petri 2001b
    1. Petri WA Jr. Drug used in the chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. In: Hardman JG, Limbird LE, editors(s). Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 10th edition. New York: McGraw Hill, 2001:1273-94. [ISBN: 0-07-135469-7]
R 2018
    1. R M, V R, Nambi PS, Ramakrishnan B, Gopalakrishnan R, Sathyamurthy. Profile of infective endocarditis: at a tertiary care referral centre. Journal of the Association of Physicians of India 2018;66(6):60-5. [PMID: ] - PubMed
Review Manager 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sadeghi 2019
    1. Sadeghi S, Wadia S, Lluri G, Tarabay J, Fernando A, Salem M, et al. Risk factors for infective endocarditis following transcatheter pulmonary valve replacement in patients with congenital heart disease. Catheterization and Cardiovascular Interventions 2019;94(4):625-35. [PMID: ] - PubMed
Salvador 2017
    1. Salvador VB, Chapagain B, Joshi A, Brennessel DJ. Clinical risk factors for infective endocarditis in Staphylococcus aureus bacteremia. Texas Heart Institute Journal 2017;44(1):10-5. [PMID: ] - PMC - PubMed
Saraste 2019
    1. Saraste A, Knuuti J. Guidelines in review: Comparison of ESC and AHA guidance for the diagnosis and management of infective endocarditis in adults. Are the differences clinically relevant? The European perspective. Journal of Nuclear Cardiology 2019;26(1):309-12. [PMID: ] - PubMed
Selton‐Suty 2019
    1. Selton-Suty C, Goehringer F, Venner C, Thivilier C, Huttin O, Hoen B. Complications and prognosis of infective endocarditis [Complications et pronostic de l'endocardite infectieuse]. Presse Medicale 2019;48(5):532-8. [PMID: ] - PubMed
Senn 2007
    1. Senn S, Bretz F. Power and sample size when multiple endpoints are considered. Pharmaceutical Statistics 2007;6(3):161-70. [PMID: ] - PubMed
Shannon 2010
    1. Shannon O, Morgelin M, Rasmussen M. Platelet activation and biofilm formation by Aerococcus urinae, an endocarditis-causing pathogen. Infection and Immunity 2010;78(10):4268-75. [PMID: ] - PMC - PubMed
Shao 2019
    1. Shao IY, Elkind MSV, Boehme AK. Risk factors for stroke in patients with sepsis and bloodstream infections. Stroke 2019;50(5):1046-51. [PMID: ] - PMC - PubMed
Shrestha 2014
    1. Shrestha NK, Mason P, Gordon SM, Neuner E, Nutter B, O'Rourke C, et al. Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study. Journal of Antimicrobial Chemotherapy 2014;69(5):1407-15. [PMID: ] - PubMed
Singer 2017
    1. Singer M, Alkady H, Mohsen T, Roushdy A, Akl AK, Mashaal M. Predictors of surgical outcome in isolated tricuspid valve endocarditis: single center experience of 60 patients. Thoracic and Cardiovascular Surgeon 2017;65(8):634-8. [PMID: ] - PubMed
Skinner 2016
    1. Skinner S, Wudel B, Sanche SE. Microbiology of infective endocarditis and microbiologic diagnosis. In: Chan K-L, Embil JM, editors(s). Endocarditis: Diagnosis and Management. London: Springer-Verlag, 2016:49-66. [DOI: 10.1007/978-3-319-27784-4_9] - DOI
Slipczuk 2013
    1. Slipczuk L, Codolosa JN, Davila CD, Romero-Corral A, Yun J, Pressman GS, et al. Infective endocarditis epidemiology over five decades: a systematic review. PLOS ONE 2013;8(12):e82665. [PMID: ] - PMC - PubMed
Song 2015
    1. Song JK. Infective endocarditis involving an apparently structurally normal valve: new epidemiological trend? Korean Journal of Internal Medicine 2015;30(4):434-42. [PMID: ] - PMC - PubMed
Sormani 2017
    1. Sormani MP. The most frequently asked question to a statistician: the sample size. Multiple Sclerosis 2017;23(5):644-6. [PMID: ] - PubMed
Sotero 2019
    1. Sotero FD, Rosario M, Fonseca AC, Ferro JM. Neurological complications of infective endocarditis. Current Neurology and Neuroscience Reports 2019;19(5):23. [PMID: ] - PubMed
Sterne 2011
    1. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002. [PMID: ] - PubMed
Sun 2015
    1. Sun BJ, Choi SW, Park KH, Jang JY, Kim DH, Song JM, et al. Infective endocarditis involving apparently structurally normal valves in patients without previously recognized predisposing heart disease. Journal of the American College of Cardiology 2015;65(3):307-9. [PMID: ] - PubMed
Süzük 2016
    1. Süzük S, Kaskatepe B, Cetin M. Antimicrobial susceptibility against penicillin, ampicillin and vancomycin of viridans group Streptococcus in oral microbiota of patients at risk of infective endocarditis. Le Infezioni in Medicina 2016;24(3):190-3. [PMID: ] - PubMed
Tam 2016
    1. Tam JW, Shaikh N, Bybel B, Jassal DS. Diagnostic approach to endocarditis. In: Chan K‐L, Embil JM, editors(s). Endocarditis: Diagnosis and Management. London: Springer‐Verlag, 2016:91-116. [DOI: 10.1007/978-3-319-27784-4] - DOI
Tao 2017
    1. Tao E, Wan L, Wang W, Luo Y, Zeng J, Wu X. The prognosis of infective endocarditis treated with biological valves versus mechanical valves: a meta-analysis. PLOS ONE 2017;12(4):e0174519. [PMID: ] - PMC - PubMed
Thiene 2006
    1. Thiene G, Basso C. Pathology and pathogenesis of infective endocarditis in native heart valves. Cardiovascular Pathology 2006;15(5):256-63. [PMID: ] - PubMed
Thornhill 2015
    1. Thornhill MH, Dayer MJ, Prendergast B, Baddour LM, Jones S, Lockhart PB. Incidence and nature of adverse reactions to antibiotics used as endocarditis prophylaxis. Journal of Antimicrobial Chemotherapy 2015;70(8):2382-8. [PMID: ] - PMC - PubMed
Thurlow 2010
    1. Thurlow LR, Thomas VC, Narayanan S, Olson S, Fleming SD, Hancock LE. Gelatinase contributes to the pathogenesis of endocarditis caused by Enterococcus faecalis. Infection and Immunity 2010;78(11):4936-43. [PMID: ] - PMC - PubMed
Tissot‐Dupont 2017
    1. Tissot-Dupont H, Casalta JP, Gouriet F, Hubert S, Salaun E, Habib G, et al. International experts' practice in the antibiotic therapy of infective endocarditis is not following the guidelines. Clinical Microbiology and Infection 2017;23(10):736-9. [PMID: ] - PubMed
Torres 2010
    1. Torres MJ, Blanca M. The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams. Medical Clinics of North America 2010;94(4):805-20. [PMID: ] - PubMed
Tran 2019
    1. Tran PM, Feiss M, Kinney KJ, Salgado-Pabon W. ɸSa3mw prophage as a molecular regulatory switch of Staphylococcus aureus beta-toxin production. Journal of Bacteriology 2019;201(14):e00766-18. [PMID: ] - PMC - PubMed
Ursi 2019
    1. Ursi MP, Durante Mangoni E, Rajani R, Hancock J, Chambers JB, Prendergast B. Infective endocarditis in the elderly: diagnostic and treatment options. Drugs and Aging 2019;36(2):115-24. [PMID: ] - PubMed
Varela 2019
    1. Varela Barca L, Navas Elorza E, Fernendez-Hidalgo N, Moya Mur JL, Muriel Garcia A, Fernandez-Felix BM, et al. Prognostic factors of mortality after surgery in infective endocarditis: systematic review and meta-analysis. Infection 2019;47(6):879-95. [PMID: ] - PubMed
Vilhena 2012
    1. Vilhena C, Bettencourt A. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Reviews in Medicinal Chemistry 2012;12(3):202-9. [PMID: ] - PubMed
Vinh 2016
    1. Vinh DC, Embil JM. Treatment of endocarditis. In: Chan K-L, Embil JM, editors(s). Endocarditis: Diagnosis and Management. London: Springer-Verlag, 2016:181-280. [DOI: 10.1007/978-3-319-27784-4_9] - DOI
Vogkou 2016
    1. Vogkou CT, Vlachogiannis NI, Palaiodimos L, Kousoulis AA. The causative agents in infective endocarditis: a systematic review comprising 33,214 cases. European Journal of Clinical Microbiology and Infectious Diseases 2016;35(8):1227-45. [PMID: ] - PubMed
Von Reyn 1981
    1. Von Reyn CF, Levy BS, Arbeit RD, Friedland G, Crumpacker CS. Infective endocarditis: an analysis based on strict case definitions. Annals of Internal Medicine 1981;94(4 Part 1):505-18. [PMID: ] - PubMed
Wang 2014
    1. Wang SZ, Hu JT, Zhang C, Zhou W, Chen XF, Jiang LY, et al. The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials. BMJ Open 2014;4(6):e004744. [PMID: ] - PMC - PubMed
Warren 2008
    1. Warren RE. Daptomycin in endocarditis and bacteraemia: a British perspective. Journal of Antimicrobial Chemotherapy 2008;62 Suppl 3:iii25-33. [PMID: ] - PubMed
Wei 2019
    1. Wei XB, Su Z, Liu YH, Wang Y, Huang JL, Yu DQ, et al. Age, creatinine, and ejection fraction (ACEF) score: a simple risk-stratified method for infective endocarditis. QJM: Monthly Journal of the Association of Physicians 2019;112(12):900-6. [PMID: ] - PubMed
Werdan 2014
    1. Werdan K, Dietz S, Loffler B, Niemann S, Bushnaq H, Silber RE, et al. Mechanisms of infective endocarditis: pathogen-host interaction and risk states. Nature Reviews. Cardiology 2014;11(1):35-50. [PMID: ] - PubMed
Widmer 2006
    1. Widmer E, Que YA, Entenza JM, Moreillon P. New concepts in the pathophysiology of infective endocarditis. Current Infectious Disease Reports 2006;8(4):271-9. [PMID: ] - PubMed
Wong‐Beringer 2011
    1. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. International Journal of Antimicrobial Agents 2011;37(2):95-101. [PMID: ] - PubMed
Yoshioka 2018
    1. Yoshioka D, Toda K, Yokoyama JY, Matsuura R, Miyagawa S, Kainuma S, et al. Diabetes mellitus adversely affects mortality and recurrence after valve surgery for infective endocarditis. Journal of Thoracic and Cardiovascular Surgery 2018;155(3):1021-9.e5. [PMID: ] - PubMed
Yung 2007
    1. Yung D, Kottachchi D, Neupane B, Haider S, Loeb M. Antimicrobials for right-sided endocarditis in intravenous drug users: a systematic review. Journal of Antimicrobial Chemotherapy 2007;60(5):921-8. [PMID: ] - PubMed
Şimşek‐Yavuz 2020
    1. Şimşek-Yavuz S, Akar AR, Aydoğdu S, Berzeg-Deniz D, Demir H, Hazırolan T, et al. Diagnosis, treatment and prevention of infective endocarditis: Turkish consensus report-2019. Türk Kardiyoloji Derneği arşivi 2020;48(2):187-226. [PMID: ] - PubMed

References to other published versions of this review

Marti‐Carvajal 2016
    1. Marti-Carvajal AJ, Dayer M, Conterno LO, Gonzalez Garay AG, Marti-Amarista CE, Simancas-Racines D. A comparison of different antibiotic regimens for the treatment of infective endocarditis. Cochrane Database of Systematic Reviews 2016, Issue 4. [DOI: 10.1002/14651858.CD009880.pub2] [PMID: ] - DOI - PubMed

MeSH terms